Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
Ratios
6 Sheets · Starting from 2024Margins, Growth Rates In %
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross Margin | - - | - - | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | - - | - - | - - | |
|
EPS Growth
|
- - | -19.38 | 20.78 | -17.21 | -19.58 | -9.94 | |
| EPS USD | -129.00 | -154.00 | -122.00 | -143.00 | -171.00 | -188.00 | |
| Return on Assets (ROA) | -7.06 | -60.69 | -26.04 | -30.40 | -51.98 | -38.90 | |
| Return on Equity (ROE) | -116.48 | -70.57 | -27.44 | -33.36 | -58.20 | -41.98 | |
| Return on Invested Capital (ROIC) | -8.76 | -67.62 | -27.20 | -33.05 | -54.57 | -43.83 | |
| Solvency | |||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 74.07 | 2.92 | 0.83 | 0.46 | 0.30 | 0.02 | |
| Debt/Equity | 1,221.90 | 3.39 | 0.87 | 0.50 | 0.34 | 0.02 | |
| Debt/EBITDA | 87.98 | 148.35 | 368.28 | 314.97 | 189.29 | 235.29 | |
|
Debt/Capitalization
|
92.44 | 3.28 | 0.87 | 0.50 | 0.34 | 0.02 | |
| Long-Term Debt/Capitalization | - - | - - | 0.57 | 0.26 | 0.01 | - - | |
| Interest Debt per Share USD | 13.53 | 0.09 | 0.04 | 0.03 | 0.11 | - - | |
| Debt Growth | - - | 963.33 | 7.12 | -30.82 | -48.39 | -88.69 | |
| Liquidity | |||||||
| Current Ratio | 85.43 | 712.08 | 2,178.92 | 1,152.14 | 933.86 | 1,369.67 | |
| Quick Ratio | 85.43 | 676.43 | 2,134.64 | 1,138.09 | 871.69 | 1,318.44 | |
| Cash Ratio | 85.43 | 656.55 | 2,131.72 | 1,109.20 | 869.65 | 1,307.12 | |
| Operating Cash Flow Ratio | - - | -300 | -400 | -200 | -400 | -400 | |
| Turnover | |||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | - - | - - | - - | |
| Payables Turnover | - - | 1.77 | 41.04 | 6.61 | 97.86 | 3.23 | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | - - | - - | - - | |
| Coverage | |||||||
| Interest Coverage | - - | -10,506.56 | - - | -23,841.07 | -1,590.04 | - - | |
| Asset Coverage | 100 | 3,000 | 11,500 | 19,900 | 29,800 | 448,000 | |
| Cash Flow Coverage (CFGR) | -9.52 | -1,672.63 | -2,438.60 | -4,488.66 | -15,425.66 | -155,236.96 | |
| EBITDA Coverage | - - | -10,500 | - - | -23,800 | -1,500 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -12.97 | -9.87 | -7.63 | -25.93 | -11.05 | -5.94 | |
|
Price/Earnings (P/E)
|
-771.33 | -1,013.15 | -1,310.25 | -385.59 | -904.86 | -1,683.28 | |
| Price/Earnings Growth (PEG) | - - | -52.28 | 63.06 | -22.40 | -46.21 | -169.32 | |
|
Price/Book (P/B)
|
898.47 | 715.02 | 359.56 | 128.63 | 526.60 | 706.65 | |
| Price/Tangible Book (P/TB) | 898.47 | 715.02 | 359.56 | 128.63 | 526.60 | 706.65 | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-772.73 | -1,260.59 | -1,689.27 | -569.52 | -1,014.33 | -2,037.73 | |
| Price/Free CF (P/FCF) | -771.33 | -1,259.86 | -1,685.02 | -568.16 | -1,013.27 | -2,034.31 | |
| Price/Operating CF (P/OCF) | -772.73 | -1,260.59 | -1,689.27 | -569.52 | -1,014.33 | -2,037.73 |